EyePoint
EYPT----
EyePoint (EYPT)
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline lev...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
EyePoint Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$40.29231.02%
Forecast & RatingStrong buy
14analysts
- Strong buy78.57%
- Buy21.43%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Jul 17 at 04:34 PM
EyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight
- benzinga_article · Jul 16 at 06:46 AM
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- Unusual Whales · Jul 16 at 06:03 AM
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- PUBT · Jul 16 at 06:03 AM
EyePoint grants inducement stock options for 63,500 shares at $13.85 each
- PUBT · Jul 13 at 06:02 AM
EyePoint names Tarek Hassan chief strategic science officer
- benzinga_article · Jul 9 at 12:35 PM
9 Health Care Stocks With Whale Alerts In Today’s Session
